Treatment
CAR-T cells clinical trials
We’re tracking 488 recruiting studies that include CAR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT07395479RecruitingEarly Phase 1
CAR-T therapy study for advanced blood and solid cancers
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07377435RecruitingPhase 1
Vaccine after CAR-T therapy for multiple myeloma
This trial tests whether a personalized vaccine (DC/MM fusion) given after standard CAR-T cell therapy can help prevent the cancer from coming back. It is for people with multiple myeloma that has returned or not responded to treatment.
Boston, MassachusettsAges 18 years+ - NCT07355972RecruitingEarly Phase 1
CT1195E cell therapy for progressive scleroderma
This trial tests a new cell therapy called CT1195E for people with refractory or progressive systemic sclerosis (scleroderma) that also affects the lungs. It aims to see if the treatment is safe and can help slow or stop the disease.
Wuhan, HubeiAges 18–60 - NCT07350837RecruitingEarly Phase 1
CAR-T therapy for highly sensitized kidney transplant patients
This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.
Wuhan, HubeiAges 18–65 - NCT07250269RecruitingPhase 1
CAR-T therapy for AL amyloidosis
This trial tests a new CAR-T cell therapy (GC012F) that targets two proteins, CD19 and BCMA, on abnormal plasma cells. It's for people with AL amyloidosis who have already tried at least one treatment.
BeijingAges 18 years+ - NCT07173166Recruiting
Managing side effects after CAR-T treatment
This study tests if non-drug approaches like lifestyle changes or supportive care can reduce nerve-related side effects in people with blood cancers who are receiving CAR-T therapy. It aims to help patients feel better during treatment.
Valencia, ValenciaAges 18–80 - NCT07169500RecruitingPhase 1/Phase 2
CAR-T with or without stem cell transplant for young women with myeloma
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–50 - NCT07105735RecruitingPhase 1
RN1201 injection for hard-to-treat autoimmune diseases
This study tests an investigational injection called RN1201 for people whose autoimmune disease (like lupus, myasthenia gravis, or immune thrombocytopenia) has not responded to standard therapies. The goal is to see if it can better control the disease.
Nanjing, JiangsuAges 18 years+ - NCT06971380RecruitingPhase 2
CAR-T therapy for multiple myeloma and amyloidosis
This trial tests a new CAR-T cell treatment (HBI0101) for people with multiple myeloma or light-chain amyloidosis that has come back or stopped responding to other treatments. The therapy uses your own immune cells to fight cancer, and the goal is to see if it can help control the disease.
JerusalemAges 18 years+ - NCT07059169Recruiting
CAR-T cell therapy for severe autoimmune diseases
This trial tests a one-time CAR-T cell therapy for people with severe autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, dermatomyositis, or ANCA vasculitis. It aims to reset the immune system and reduce disease activity for those who haven't responded well to standard treatments.
Wuhan, HubeiAges 18 years+ - NCT07051850Recruiting
Quality of life study for relapsed myeloma immunotherapy
This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.
Seocho, SeoulAges 19 years+ - NCT07036250RecruitingPhase 1/Phase 2
Study of U32 for acute myeloid leukemia
This trial tests a new treatment called U32 for people with acute myeloid leukemia (AML) that has come back or not responded to prior therapy. It aims to see if targeting certain proteins on leukemia cells can help control the disease.
SuzhouAges 2–65 - NCT07031713RecruitingPhase 1
Testing CT1192 cells for lupus that hasn't responded to treatment
This trial tests a new treatment called CT1192, which uses your own immune cells (T-cells) that are modified to target and calm overactive immune cells causing lupus. It is designed for people with moderate to severe lupus that hasn't improved with standard therapies like steroids, immunosuppressants, or biologics.
Wuhan, HubeiAges 18–60 - NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60 - NCT06680752RecruitingPhase 1/Phase 2
A car-t cell therapy trial for AML or MDS
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
Charlotte, North CarolinaAges 18 years+ - NCT06522932RecruitingPhase 1
PET imaging study for people getting CAR-T therapy for lymphoma
This trial tests a special PET imaging agent (64Cu-GRIP B) to see if it can help track how well CAR-T therapy is working in people with non-Hodgkin lymphoma. It is for patients who have had at least one prior treatment and are scheduled to receive a standard CD19-targeting CAR-T product.
San Francisco, CaliforniaAges 18 years+ - NCT06241456RecruitingPhase 1
Experimental CAR-T cells targeting HER2 for advanced solid tumors
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
Gilbert, ArizonaAges 18 years+ - NCT06218602RecruitingPhase 2
Fecal transplant for lymphoma patients getting CAR T therapy
This trial tests whether giving a fecal transplant (a stool enema from a healthy donor) can improve the response to CAR T-cell therapy in people with B-cell lymphoma. It may help by restoring healthy gut bacteria that are often wiped out by strong antibiotics.
Houston, TexasAges 18 years+ - NCT06185751RecruitingPhase 1
Testing CS1 CAR-T for multiple myeloma
This study tests a new cell therapy called CS1 CAR-T, which helps your immune system attack myeloma cells that still grow after several other treatments. It's for people who have already tried at least three different types of therapy.
St Louis, MissouriAges 18 years+ - NCT06134960RecruitingPhase 1
KD-496 CAR T-cells for advanced solid tumors with NKG2DL or CLDN18.2
This trial tests a new type of immune cell therapy called KD-496, which is a CAR T-cell designed to attack tumors that have NKG2DL or CLDN18.2 markers. It may be an option for people with advanced solid tumors (commonly stomach or pancreatic cancer) who have tried at least two prior treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06144151Recruiting
Pupil check to predict CAR-T brain side effects
This study tests if checking your pupil size with a small light device can predict brain-related side effects from CAR-T cell therapy. It is for patients with certain lymphomas receiving axi-cel CAR-T treatment in the hospital.
Houston, TexasAges 18 years+ - NCT07775508RecruitingPhase 1
Car t cell therapy for relapsed or refractory b cell lymphoma
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
BeijingAges 18–75 - NCT07551362RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Gastric Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
Shenzhen, GuangdongAges 18–75 - NCT06248697RecruitingEarly Phase 1
CAR-T cells targeting MSLN with PD-1/CTLA-4 blockers for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-T cells) that target a protein called MSLN on cancer cells, and also release a special antibody to block two other proteins (PD-1 and CTLA-4) that cancers use to hide from the immune system. It is for people with advanced solid tumors like non-small-cell lung cancer or mesothelioma who have not responded to standard treatments.
Shanghai, Shanghai MunicipalityAges 18–70
Common questions
- Are there clinical trials studying CAR-T cells?
- Yes. Clin2 currently lists 488 recruiting studies that include CAR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CAR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CAR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CAR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.